{"entity":{"id":"wayshine-biopharm","kind":"company","name":"Wayshine Biopharm","aka":["Wayshine Biopharm, Inc."],"tldr":"Wayshine Biopharm is a China-based biotechnology company that leads 3 cancer trials in OnCo, testing the brain-penetrant EGFR inhibitor WSD0922-FU in non-small-cell lung cancer and small-cell lung cancer.","summary":"Wayshine Biopharm develops small-molecule targeted cancer drugs able to cross the blood-brain barrier, with a focus on brain tumours and lung cancer. Its lead product WSD0922-FU is an EGFR and EGFRvIII inhibitor in trials for EGFR-mutant non-small-cell lung cancer and glioma in China and the United States. The group parent is registered in the United States and the operating headquarters is in Shanghai. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06631989 (phase 1/2, A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advance...), NCT06868485 (phase 2, A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small...) and NCT07206498 (phase 1/2, A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"http://www.wayshinebiopharm.com"},{"label":"ClinicalTrials.gov: trials led by Wayshine Biopharm","url":"https://clinicaltrials.gov/search?lead=Wayshine%20Biopharm%2C%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06631989","nct06868485","nct07206498"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Shanghai","country":"CN","companyType":"biotech","website":"http://www.wayshinebiopharm.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/wayshine-biopharm/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"trial":[{"id":"nct06631989","kind":"trial","name":"A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06631989/"},{"id":"nct06868485","kind":"trial","name":"A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer","route":"/trials/nct06868485/"},{"id":"nct07206498","kind":"trial","name":"A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC","route":"/trials/nct07206498/"}]}}